Caribou Biosciences, Inc. Common Stock
CRBUCaribou Biosciences, Inc. is a biotechnology company focused on developing gene-editing technologies using CRISPR-Cas3 and other CRISPR-based tools. Founded in 2011, it specializes in precision gene editing for applications in agriculture, human therapeutics, and industrial biotechnology. The company's platform aims to enable more efficient, accurate, and versatile genetic modifications to address various biological challenges.
Company News
The global genome editing market is projected to grow from $9.39 billion in 2025 to $23.66 billion by 2031, driven by increased funding, CRISPR advancements, and AI integration. However, off-target effects and regulatory hurdles pose significant challenges. Key developments include AI-enhanced editing systems achieving 95% reduction in off-target...
Caribou Biosciences reported promising first clinical data for CB-011, an off-the-shelf allogeneic CAR-T cell therapy for relapsed or refractory multiple myeloma, with 92% overall response rate and a manageable safety profile.
CRISPR therapies are showing significant potential with over 25 key companies developing 30+ pipeline therapies targeting genetic disorders, with promising clinical trials across various disease areas.
The global gene editing market is projected to grow from USD 6.09 billion in 2024 to USD 15.46 billion by 2032, driven by CRISPR technology advances, therapeutic applications, and significant research funding, with North America leading market development.
Law firm investigating potential claims against Caribou Biosciences regarding allegedly misleading statements about its cell therapy product CB-010's safety, efficacy, and financial prospects during July 2023-2024 period.
